Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics
— Nestlé Health Science to Make Investment through the Purchase of Nearly 7.6 Million Shares of Aimmune Stock at $19.20 per Share — — Companies Enter into Strategic Collaboration Agreement Designed to Enable the Successful Development and Commercialization of Innovative Food Allergy Therapies — —
Toggle Summary Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy
— PALISADE Completed in 2017; Topline Results Anticipated in February — — Late-Breaking Abstract Presentation at the 2018 American Academy of Allergy , Asthma & Immunology–World Allergy Organization Joint Congress in March — — PALISADE Follow-On Study, ARC004, Fully Enrolled — — RAMSES Real-World
Toggle Summary Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science
— Nestlé Health Science to Invest $98 Million in Aimmune through the Purchase of 3.24 Million Shares of Aimmune Stock at $30.27 per Share — — Companies Extend Existing Strategic Collaboration Agreement Focused on Offering Innovative Food Allergy Therapies — — Nestlé Health Science CEO Greg Behar
Toggle Summary Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 2, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann , M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors,
Toggle Summary Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 7, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas , M.D., will give his first public presentation as the company’s President and CEO
Toggle Summary Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
— Phase 2 Clinical Trial Will Explore AR101 Treatment with Adjunctive Dupilumab in Peanut-Allergic Patients — — Trial Design Will Test Potential to Achieve Sustained Unresponsiveness to Peanut Following Treatment — — Conference Call Today at 8:30 a.m. Eastern Time / 5:30 a.m.
Toggle Summary Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 11, 2015-- Aimmune Therapeutics, Inc. , today announced the closing of its initial public offering of 11,499,999 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, which includes the
Toggle Summary Aimmune Therapeutics Announces Closing of Public Offering of Common Stock
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 26, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the completion of its previously announced underwritten public offering of 5,500,000
Toggle Summary Aimmune Therapeutics Announces COO Transition
— COO Howard Raff to Retire from Leadership Position to Focus on Future Pipeline Development — — Aimmune Builds Clinical Team with Key Allergist / Immunologist Hires — BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 9, 2015-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented at EAACI 2018
— In U.S. Survey , Allergists Want Consensus in Oral Immunotherapy Terminology — — U.S. Allergists Preferred “Tolerated Dose” as the Most Clinically Relevant Term to Communicate Desensitization Levels to Oral Immunotherapy Patients — BRISBANE, Calif. & MUNICH, Germany --(BUSINESS WIRE)--May 29,